Back
Rate this talk
Your peers have not rated this talk yet.
4-minute watch | Talk 2 of 5

ASH 2025: Expert Perspective

Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-cell Therapy (CAR T) in Newly Authorized Treatment Centers (ATCs) in the United States (US)

Dr Olalekan Oluwole
PERSPECTIVE
ASH
Read more

Talks in this series

n/a
4-minute watch | Talk 1 of 5
ASH 2025: Expert Perspective
Real-World Healthcare Resource Utilization (HCRU) Following CAR T-Cell Therapy in US Patients treated in Newly Authorized Treatment Centers
n/a
4-minute watch
ASH 2025: Expert Perspective

Real-World Healthcare Resource Utilization (HCRU) Following CAR T-Cell Therapy in US Patients treated in Newly Authorized Treatment Centers

n/a
4-minute watch | Talk 2 of 5
Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-cell Therapy (CAR T) in Newly Authorized Treatment Centers (ATCs) in the United States (US)
Dr Olalekan Oluwole
n/a
4-minute watch

Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-cell Therapy (CAR T) in Newly Authorized Treatment Centers (ATCs) in the United States (US)

Dr Olalekan Oluwole

n/a
4-minute watch | Talk 3 of 5
US Cost Consequence and Time Toxicity Model for Advanced Therapies in the Treatment for Relapsed/Refractory Third-Line or Later Diffuse Large B-cell Lymphoma: A Comparison of Axicabtagene Ciloleucel with Bispecific Antibodies
Dr Olalekan Oluwole
n/a
4-minute watch

US Cost Consequence and Time Toxicity Model for Advanced Therapies in the Treatment for Relapsed/Refractory Third-Line or Later Diffuse Large B-cell Lymphoma: A Comparison of Axicabtagene Ciloleucel with Bispecific Antibodies

Dr Olalekan Oluwole

n/a
3-minute watch | Talk 4 of 5
Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in the United States (US)
Dr Olalekan Oluwole
n/a
3-minute watch

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in the United States (US)

Dr Olalekan Oluwole

n/a
| Talk 5 of 5
Real World Comparison of Commercial CAR T-Cell Constructs for the Treatment of LBCL, How is this data different to other real world evidence and what does this mean for patients
Dr Megan Melody
n/a

Real World Comparison of Commercial CAR T-Cell Constructs for the Treatment of LBCL, How is this data different to other real world evidence and what does this mean for patients

Dr Megan Melody

n/a
4-minute watch | Talk 1 of 5
ASH 2025: Expert Perspective
Real-World Healthcare Resource Utilization (HCRU) Following CAR T-Cell Therapy in US Patients treated in Newly Authorized Treatment Centers
n/a
4-minute watch
ASH 2025: Expert Perspective

Real-World Healthcare Resource Utilization (HCRU) Following CAR T-Cell Therapy in US Patients treated in Newly Authorized Treatment Centers

n/a
4-minute watch | Talk 2 of 5
Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-cell Therapy (CAR T) in Newly Authorized Treatment Centers (ATCs) in the United States (US)
Dr Olalekan Oluwole
n/a
4-minute watch

Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-cell Therapy (CAR T) in Newly Authorized Treatment Centers (ATCs) in the United States (US)

Dr Olalekan Oluwole

n/a
4-minute watch | Talk 3 of 5
US Cost Consequence and Time Toxicity Model for Advanced Therapies in the Treatment for Relapsed/Refractory Third-Line or Later Diffuse Large B-cell Lymphoma: A Comparison of Axicabtagene Ciloleucel with Bispecific Antibodies
Dr Olalekan Oluwole
n/a
4-minute watch

US Cost Consequence and Time Toxicity Model for Advanced Therapies in the Treatment for Relapsed/Refractory Third-Line or Later Diffuse Large B-cell Lymphoma: A Comparison of Axicabtagene Ciloleucel with Bispecific Antibodies

Dr Olalekan Oluwole

n/a
3-minute watch | Talk 4 of 5
Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in the United States (US)
Dr Olalekan Oluwole
n/a
3-minute watch

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in the United States (US)

Dr Olalekan Oluwole

n/a
| Talk 5 of 5
Real World Comparison of Commercial CAR T-Cell Constructs for the Treatment of LBCL, How is this data different to other real world evidence and what does this mean for patients
Dr Megan Melody
n/a

Real World Comparison of Commercial CAR T-Cell Constructs for the Treatment of LBCL, How is this data different to other real world evidence and what does this mean for patients

Dr Megan Melody

Interested in this topic?

Find more like this

  This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.

HCP Check with options

Select an option below that best describes your role to tailor the content you see:

A CAR T referrer
A CAR T nurse
A CAR T treater
Other healthcare professional